Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
Open Access
- 15 January 2023
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (2) , 281-284
Abstract
Crizotinib shows antitumor activity against C-ros oncogene 1-rearranged non-small-cell lung cancer (NSCLC). While corrected QT interval (QTc) prolongation and bradycardia are known cardiac adverse effects, little is known about crizotinib-related heart failure. Our patient with C-ros oncogene 1-rearranged NSCLC on a reduced dose of crizotinib (200 mg twice daily) after initially experiencing bradycardia and QTc prolongation developed crizotinib-induced heart failure. With further dose reduction (250 mg once daily), there was no recurrence of any cardiac adverse effects, and the patient achieved a long-term response. Although crizotinib can cause heart failure, continuation of crizotinib at a low dose may be an effective treatment option.Keywords
This publication has 13 references indexed in Scilit:
- Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer TherapeuticsFrontiers in Physiology, 2017
- Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsAnnals of Oncology, 2016
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2016
- Crizotinib-Induced Cardiotoxicity: The Importance of a Proactive Monitoring and ManagementFuture Oncology, 2015
- Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case reportBMC Research Notes, 2015
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET FusionsThe Oncologist, 2013
- Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor MutationsJournal of Thoracic Oncology, 2011
- Cardiovascular complications of conventional and targeted adjuvant breast cancer therapyAnnals of Oncology, 2010